Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (ABT)

Abbott Laboratories logoAbbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: ABT
  • CUSIP: 00282410
Key Metrics:
  • Previous Close: $44.81
  • 50 Day Moving Average: $44.46
  • 200 Day Moving Average: $41.30
  • 52-Week Range: $36.76 - $45.84
  • Trailing P/E Ratio: 47.81
  • Foreward P/E Ratio: 16.29
  • P/E Growth: 1.63
  • Market Cap: $77.41B
  • Outstanding Shares: 1,727,997,000
  • Beta: 0.97
  • Net Margins: 6.71%
  • Return on Equity: 15.74%
  • Return on Assets: 8.27%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.25%

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (?)
Ratings Breakdown: 4 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $48.50 (8.23% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/14/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$48.00MediumView Rating Details
3/11/2017Jefferies Group LLCReiterated RatingBuy$51.00 -> $52.00N/AView Rating Details
3/1/2017Royal Bank of CanadaBoost Price TargetOutperform$46.00 -> $50.00N/AView Rating Details
9/19/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$45.00N/AView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
7/21/2016Barclays PLCBoost Price TargetOverweight$48.00 -> $50.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse Group AGReiterated RatingBuyN/AView Rating Details
5/12/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/21/2016Cowen and CompanyReiterated RatingNeutral -> Buy$44.00 -> $48.00N/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Stifel NicolausBoost Price TargetBuy$42.00 -> $47.00N/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016Goldman Sachs Group IncLower Price TargetNeutral$44.00 -> $40.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
1/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$50.00N/AView Rating Details
5/27/2015Evercore Partners Inc.Initiated CoverageBuy$54.00N/AView Rating Details
5/26/2015Evercore ISIInitiated CoverageBuy$54.00N/AView Rating Details
4/23/2015JPMorgan Chase & Co.Boost Price TargetNeutral$46.00 -> $48.00N/AView Rating Details
(Data available from 3/23/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE:ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2017Q416$0.65$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.69$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.59$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
Current Year EPS Consensus Estimate: $2.45 EPS
Next Year EPS Consensus Estimate: $2.75 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.39$0.40$0.39
Q2 20165$0.51$0.54$0.53
Q3 20163$0.58$0.60$0.59
Q4 20163$0.63$0.67$0.65
Q1 20172$0.43$0.50$0.47
Q2 20172$0.60$0.62$0.61
Q3 20172$0.64$0.69$0.67
Q4 20172$0.68$0.74$0.71
Q1 20181$0.53$0.53$0.53
Q2 20181$0.69$0.69$0.69
Q3 20181$0.78$0.78$0.78
Q4 20181$0.85$0.85$0.85
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Next Dividend:5/15/2017
Annual Dividend:$1.06
Dividend Yield:2.37%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:113.98% (Trailing 12 Months of Earnings)
43.27% (Based on This Year's Estimates)
38.55% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE:ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 62.20%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
News IconAbbott Laboratories (ABT) Receives Average Rating of "Buy" from Analysts (NYSE:ABT) - March 23 at 11:08 AM logoAbbott Hosts Conference Call for First-Quarter Earnings (NYSE:ABT) - March 22 at 3:17 PM logoCan Abbott Outperform Despite Alere? (NYSE:ABT) - March 22 at 3:17 PM logoABBOTT LABORATORIES Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balan (NYSE:ABT) - March 22 at 3:17 PM logoNot All's Well With Abbott's Absorb Stent? (NYSE:ABT) - March 22 at 1:24 AM logo3:18 am Abbott Labs reports late-breaking data indicating MitraClip showed 92.8% procedural success rate (NYSE:ABT) - March 20 at 5:19 AM logoLate-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care (NYSE:ABT) - March 19 at 3:15 PM logoLate-Breaking Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease (NYSE:ABT) - March 18 at 3:15 PM logoIXJ, ABT, TMO, DHR: Large Outflows Detected at ETF (NYSE:ABT) - March 18 at 1:24 AM logo3 Reasons to Love Abbott Laboratories (ABT) Stock - (NYSE:ABT) - March 17 at 3:17 PM logo3 Reasons to Love Abbott Laboratories (ABT) Stock (NYSE:ABT) - March 17 at 10:31 AM logoAbbott Laboratories' (ABT) Management Presents at Barclays Capital 2017 Global Healthcare Conference (Transcript) (NYSE:ABT) - March 16 at 4:46 PM logoHow to Get Diabetics Addicted to Data (NYSE:ABT) - March 16 at 4:46 PM logoAlere Delays Filing for 2nd Year in a Row (NYSE:ABT) - March 16 at 4:46 PM logoDealpolitik: Abbott Vs. Alere: A Case for Revising the MAE (NYSE:ABT) - March 15 at 3:20 PM
News IconAbbott Laboratories (ABT) Rating Lowered to Market Perform at BMO Capital Markets (NYSE:ABT) - March 15 at 12:24 AM logoAbbott Laboratories Downgraded by MBO (NYSE:ABT) - March 14 at 8:17 PM logoAbbVie, Abbott Laboratories, Amplify Snacks, Skyworks Solutions ... - (NYSE:ABT) - March 14 at 3:15 PM logoBMO On Abbott Labs: 'It's Likely Time For The Stock To Take A Pause' - Benzinga (NYSE:ABT) - March 14 at 3:15 PM logoAbbott Laboratories Stock Downgraded by BMO (NYSE:ABT) - March 14 at 3:15 PM logoBMO On Abbott Labs: 'It's Likely Time For The Stock To Take A Pause' (NYSE:ABT) - March 14 at 3:15 PM logoABBOTT LABORATORIES Files SEC form 8-K, Change in Directors or Principal Officers (NYSE:ABT) - March 14 at 3:15 PM
News IconAbbott Laboratories (ABT) Stock Rating Upgraded by TheStreet (NYSE:ABT) - March 13 at 5:57 PM logoFormer Angels star faces federal insider trading charges (NYSE:ABT) - March 10 at 3:16 PM logoAbbott to Present at Barclays Capital 2017 Global Healthcare Conference (NYSE:ABT) - March 8 at 8:15 PM logoAbbVie Is a Screaming Dividend Growth Buy... Here's Why (NYSE:ABT) - March 8 at 8:15 PM logoNew Study Results May Lead to a New Standard of Care for In Vitro Fertilization Treatment (NYSE:ABT) - March 8 at 3:15 PM logoCarson Block's short seller's strategy (NYSE:ABT) - March 7 at 3:15 PM logoAbbott Announces Results of Early Tenders and Consents in Exchange Offers and Execution of Supplemental Indenture (NYSE:ABT) - March 7 at 3:15 PM logoIHI, ABT, TMO, DHR: Large Outflows Detected at ETF (NYSE:ABT) - March 2 at 8:17 PM logoTop Analysts Upgrades and Downgrades: Abbott Labs, General ... - 24/7 Wall St. (NYSE:ABT) - March 2 at 3:16 PM logoAlere's Bad News Tests the Limits of Patience (NYSE:ABT) - March 1 at 3:15 PM logoAlere delays annual filing for second year in a row (NYSE:ABT) - March 1 at 3:15 PM logoDiagnostic company Alere says to delay filing annual report (NYSE:ABT) - March 1 at 8:40 AM logoAbbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue? - Nasdaq (NYSE:ABT) - February 27 at 5:15 AM logoAbbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue? (NYSE:ABT) - February 27 at 5:15 AM logo(ABBV), Abbott Laboratories (NYSE:ABT) - 2 Dividend Aristocrats ... - Benzinga (NYSE:ABT) - February 24 at 9:31 AM logoABBOTT LABORATORIES Financials (NYSE:ABT) - February 23 at 3:17 PM


Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, February 17th. Stockholders of record on Friday, April 14th will be given a dividend of $0.265 per share on Monday, May 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date is Tuesday, April 11th.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Monday, February, 6th. The company reported $0.65 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.65. The business earned $5.33 billion during the quarter, compared to the consensus estimate of $5.41 billion. Abbott Laboratories had a return on equity of 15.74% and a net margin of 6.71%. The business's revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 earnings per share.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, April, 18th 2017.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY17 earnings guidance on Wednesday, January, 25th. The company provided EPS guidance of $2.40-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.42. Abbott Laboratories also updated its Q1 guidance to $0.42-0.44 EPS.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

17 brokers have issued twelve-month price objectives for Abbott Laboratories' shares. Their predictions range from $40.00 to $55.00. On average, they expect Abbott Laboratories' share price to reach $48.50 in the next year.

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (4.60%), Norges Bank (0.90%), FMR LLC (0.94%), Franklin Resources Inc. (0.60%), Institutional Capital LLC (0.51%) and Dimensional Fund Advisors LP (0.46%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, J Scott White, Jaime Contreras, Jared Watkin, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Thrivent Financial for Lutherans, FMR LLC, AQR Capital Management LLC, Institutional Capital LLC, Franklin Resources Inc., Aberdeen Asset Management PLC UK and Orbimed Advisors LLC. Company insiders that have sold Abbott Laboratories stock in the last year include Brian B Yoor, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Westwood Holdings Group Inc., Dimensional Fund Advisors LP, Asset Management One Co. Ltd., Renaissance Technologies LLC, State Street Corp, Russell Investments Group Ltd. and Loomis Sayles & Co. L P. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abbott Laboratories stock cost?

One share of Abbott Laboratories stock can currently be purchased for approximately $44.81.

Abbott Laboratories (ABT) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by Staff